Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
► Estadiamiento:
Etapa IV >20
Curigliano G, Mayer EL, Burstein HJ, Winer EP, Goldhirsch A (2010): Cardiac toxicity
from systemic cancer therapy: a comprehensive review. ProgCardiovasc Dis. 53: 94-
104.
Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL
(2010): American Society of Clinical Oncology; College of American Pathologists.
American Society of Clinical Oncology/College of American Pathologists guideline
recommendations for immunohistochemical testing of estrogen and progesterone
receptors in breast cancer. Arch Pathol Lab Med. 134:48-72.
Intra M, Trifirò G, Galimberti V (2007): Second axillary sentinel node biopsy for
ipsilateral breast tumour recurrence. Br J Surg. 94: 1216-1219.
Kim SI, Sohn J, Koo JS, Park SH, Park HS, Park BW (2010): Molecular subtypes and
tumor response to neoadjuvant chemotherapy in patients with locally advanced breast
cancer. Oncology. 79: 324-330.
Lutz S, Berk L, Chang E (2011): American Society for Radiation Oncology (ASTRO).
Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J
RadiatOncolBiol Phys. 79:965-976.
Pusztai L, Viale G, Kelly CM, Hudis CA (2010): Estrogen and HER-2 receptor
discordance between primary breast cancer and metastasis. Oncologist. 15:1164-
1168.
Soriano JL, Lima M, Batista N, González J, Pangui M (2009): Evaluación del uso del
esquema de paclitaxel con carboplatino en pacientes con cáncer de mama
metastásico. RevCubana Med [revista en la Internet]. [citado 2012 Jun 16] ; 48:
Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-
75232009000200003&lng=es.
Thompson AM, Jordan LB, Quinlan P (2010): Breast Recurrence in Tissues Study
Group. Prospective comparison of switches in biomarker status between primary and
recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). Breast
Cancer Res. 12:R92.
Wo JY, Taghian AG, Nguyen PL (2010): The association between biological subtype
and isolated regional nodal failure after breast-conserving therapy. Int J Radiat Oncol
Biol Phys. 77: 188-196.
Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical
Oncology/College of American Pathologists guideline recommendations for human
epidermal growth factor receptor 2 testing in breast cancer. J ClinOncol. 2007;25:118–
45.
Vía de Modo de
Esquema Dosis
administración administración
HER (ciclos cada tres semanas)
8 mg/kg IV (90 min Inf.) D 1 (dosis de
carga)
Trastuzumab
6 mg/kg IV (60 min Inf.) (dosis de
mantenimiento)
HER (ciclos semanales)
4 mg/kg IV (60 min Inf.) D 1 (dosis de
carga)
Trastuzumab
2 mg/kg IV (30 min Inf.) (dosis de
mantenimiento)
Pamidronato (ciclos cada 3-4 semanas)
Pamidronato 90 mg IV (2h Inf.) D1
ZOL (ciclos cada 3-4 semanas)
Ácido Zoledrónico 4 mg IV (15−30 min Inf.) D1
TAM (antiestrógeno)
Tamoxifeno 20mg Oral (1v/d) x 5 años
FEM (inhibidores de la aromatasa)
Letrozol 2,5 mg Oral (1v/d) x 5-10 años
LHRH (ciclos cada 4 semanas)
Goserelina 3,6 mg SC x 2-5 años